1. Home
  2. KROS vs CCNE Comparison

KROS vs CCNE Comparison

Compare KROS & CCNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KROS
  • CCNE
  • Stock Information
  • Founded
  • KROS 2015
  • CCNE 1865
  • Country
  • KROS United States
  • CCNE United States
  • Employees
  • KROS N/A
  • CCNE N/A
  • Industry
  • KROS Biotechnology: Pharmaceutical Preparations
  • CCNE Major Banks
  • Sector
  • KROS Health Care
  • CCNE Finance
  • Exchange
  • KROS Nasdaq
  • CCNE Nasdaq
  • Market Cap
  • KROS 565.0M
  • CCNE 775.5M
  • IPO Year
  • KROS 2020
  • CCNE N/A
  • Fundamental
  • Price
  • KROS $15.62
  • CCNE $25.68
  • Analyst Decision
  • KROS Buy
  • CCNE Hold
  • Analyst Count
  • KROS 14
  • CCNE 1
  • Target Price
  • KROS $20.56
  • CCNE $29.00
  • AVG Volume (30 Days)
  • KROS 412.4K
  • CCNE 102.5K
  • Earning Date
  • KROS 11-05-2025
  • CCNE 10-20-2025
  • Dividend Yield
  • KROS N/A
  • CCNE 2.81%
  • EPS Growth
  • KROS N/A
  • CCNE 2.16
  • EPS
  • KROS 0.47
  • CCNE 2.38
  • Revenue
  • KROS $232,844,000.00
  • CCNE $224,762,000.00
  • Revenue This Year
  • KROS $5,998.31
  • CCNE $18.69
  • Revenue Next Year
  • KROS N/A
  • CCNE $29.21
  • P/E Ratio
  • KROS $33.74
  • CCNE $10.77
  • Revenue Growth
  • KROS 85820.30
  • CCNE 4.79
  • 52 Week Low
  • KROS $9.12
  • CCNE $19.32
  • 52 Week High
  • KROS $72.37
  • CCNE $29.29
  • Technical
  • Relative Strength Index (RSI)
  • KROS 57.13
  • CCNE 53.61
  • Support Level
  • KROS $15.34
  • CCNE $25.21
  • Resistance Level
  • KROS $15.85
  • CCNE $26.35
  • Average True Range (ATR)
  • KROS 0.45
  • CCNE 0.48
  • MACD
  • KROS -0.02
  • CCNE -0.17
  • Stochastic Oscillator
  • KROS 57.08
  • CCNE 27.01

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

About CCNE CNB Financial Corporation

CNB Financial Corp is providing integrated financial solutions, which create value for both consumers and businesses. These solutions encompass deposit accounts, private banking, real estate, commercial, industrial, residential and consumer loans and lines of credit, credit cards, treasury services, online banking, mobile banking, merchant credit card processing, remote deposit and accounts receivable handling. It derives revenue through the operations as a full-service bank engaging in a full range of banking activities and services, including trust and wealth management services, for individual, business, governmental, and institutional customers. The company branch are located in Pennsylvania, Ohio, New York and Virginia.

Share on Social Networks: